CDK4 and breast carcinoma: On the contrary, the second generation of CDK inhibitors show better anti-tumor activity and selectivity, especially those targeting CDK4/6, like palbociclib, ribociclib, abemaciclib, etc., which can inhibit RB phosphorylation and block the cell cycle in G1 phase, preventing the proliferation of breast cancer (99, 100).